Doctor Bond 123266 Price Prediction on Its First Day of Trading

PortfolioAlert · 2026-04-03T01:33:39+00:00

Shareholders lack confidence in Dr. Eye's debt issuance performance, and market volatility has increased, making forecasts more difficult. Although the company incorporates AI technology elements, it still struggles to withstand external shocks. Concerns remain over the premium rate and conversion value of the debt issuance, and investors should exercise caution.

PortfolioAlert

2026-04-03 01:33:39

Abstract generation in progress

During the Qingming season, drizzle falls in countless threads;
Shareholders’ accounts are about to be heartbroken.
——For those who bought Ph.D. Goggles with debt conversion at 28.1 yuan on the “low” and also aren’t confident about their forecasts
In March, it starts a pattern of downpours + a blowout decline;
The prediction begins with hellish-level difficulty.
Ph.D. Goggles originally came with an AI concept, had technological elements, yet it still couldn’t withstand the war-related volatility launched by the United States.
The bonds belong to the commercial retail sector; including the fact that it only has three members, and right now the premium rate over the 100 yuan par value is, astonishingly, the highest in the sector.
Conversion value 77.19 Remaining principal and interest 115.50 Issuance size (hundred million) 3.750 Restricted issuance size (hundred million) 1.528
From the premium rate perspective, calculating at a 50% premium gives 115.785 (discarded).
From the equity perspective, PATHON calculates 135-153 yuan.
From overlaying the long-term trend of the underlying stock with cycle theory, the rechecked price is 153 dropping back to around 143 for a close.
The entire theory behind debt conversion is all completely ruined—there’s no safety cushion. Those who sold at the opening on the ex-rights day, only selling above 150 yuan on the first day might have a chance to break even.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.